Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

TY - JOUR

T1 - Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

AU - Bean, J.

AU - Riely, G. J.

AU - Balak, M.

AU - Marks, J. L.

AU - Ladanyi, M.

AU - Miller, V. A.

AU - Pao, W.

N1 - 8056 Background: Somatic mutations in exons encoding the tyrosine kinase domain of EGFR are associated with increased sensitivity of lung adenocarcinomas to the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. In almost half of cases examined, acquired drug resistance is associated with a specific secondary somatic mutation in exon 20 that leads to substitution of methionine for threonine at position 790 (T790M).

PY - 2008/5/20

Y1 - 2008/5/20

UR - http://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.8056

U2 - 10.1200/JCO.2008.26.15_SUPPL.8056

DO - 10.1200/JCO.2008.26.15_SUPPL.8056

M3 - Article

VL - 26

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -